In the Claims

Claims 1-4 (canceled)

- 5. (currently amended) A DNA fragment comprising a nucleic acid sequence according to claim 1-4 claim 25.
- 6. (currently amended) Recombinant A recombinant DNA molecule comprising a nucleic acid sequence according to claims 1-4 or a DNA fragment according to claim 5 claim 25, under the control of a functionally linked promoter.
- 7. (currently amended) Live A live recombinant carrier comprising a nucleic acid sequence according to claims 1-4, a DNA fragment according to claim 5 or a recombinant DNA molecule according to claim 6. claim 25.
- 8. (currently amended) Host A host cell comprising a nucleic acid sequence according to claims 1-4, a DNA fragment according to claim 5, a recombinant DNA molecule according to claim 6 or a live recombinant carrier according to claim 7 claim 25.

-3-

Attorney Docket: I-2002.011 US

Customer No.: 31846

Claims 9-18 (canceled)

- 19. (currently amended) Vaccine A vaccine for combating

 Brachyspira hyodysenteriae infection , characterized in that

 it comprises comprising antibodies against a lipoprotein

 according to claims 9-14 or an immunogenic fragment of said

 lipoprotein claim 29, and a pharmaceutically acceptable

 carrier.
- 20. (currently amended) Vaccine The vaccine according to claim 19, characterized in that it comprises comprising an adjuvant.
- 21. (currently amended) Vaccine The vaccine according to claim

 19, or 20, characterized in that it comprises comprising an additional antigen derived from a virus or micro-organism—

 pathogenic to pigs another swine pathogen, an antibody against such an antigen or genetic information encoding said antigen.
- 22. (currently amended) Vaccine The vaccine according to claim
 21, characterized in that said virus or micro-organism

 pathogenic to pigs wherein said pathogen is selected from

-4-

Attorney Docket: I-2002.011 US

Customer No.: 31846

the group consisting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

Claim 23 (cancel)

- 24. (currently amended) A diagnostic kit <u>for detecting</u>

 <u>Brachyspira hyodysenteriae</u> or antibodies thereto, comprising
 <u>suitable detection means and</u> a nucleic acid sequence
 according to <u>claims 1-4 or a or primer thereof claim 25</u>, or
 a lipoprotein or <u>immunogenic antigenic fragment thereof</u>

 <u>according to claims 9-14 encoded by said sequence</u>, or
 antibodies that are reactive with a <u>said lipoprotein</u>

 <u>according to claims 9-14</u>.
- 25. (new) A nucleic acid sequence encoding an immunogenic 61kD Brachyspira hyodysenteriae lipoprotein, as measured by SDS-PAGE.

-5-

Attorney Docket: I-2002.011 US

Customer No.: 31846

- 26. (new) The nucleic acid sequence of claim 25, wherein the 61 kD Brachyspira hyodysenteriae lipoprotein has the amino acid sequence of SEQ ID NO:2.
- 27. (new) A nucleic acid sequence encoding an immunogenic 20 kD Brachyspira hyodysenteriae lipoprotein, as measured by SDS-PAGE.
- 28. (new) The nucleic acid sequence of claim 27, wherein the 20 kD Brachyspira hyodysenteriae lipoprotein has the amino acid sequence of SEQ ID NO:4.
- 29. (new) An isolated immunogenic *Brachyspira hyodysenteriae* lipoprotein of 61 kD, as measured by SDS-PAGE.
- 30. (new) The isolated immunogenic Brachyspira

 hyodysenteriae lipoprotein of claim 29 having the amino acid sequence of SEQ ID NO: 2.
- 31. (new) An isolated immunogenic *Brachyspira hyodysenteriae* lipoprotein of 20 kD, as measured by SDS-PAGE.
- 32. (new) The isolated immunogenic Brachyspira

 hyodysenteriae lipoprotein of claim 31 having the amino acid
 sequence of SEQ ID NO:4.

-6-

Attorney Docket: I-2002.011 US

Customer No.: 31846

- 33. (new) An immunogenic composition comprising an effective amount of the *Brachyspira hyodysenteriae* lipoprotein of claim 29 and a pharmaceutically acceptable carrier.
- 34. (new) An immunogenic composition comprising an effective amount of the *Brachyspira hyodysenteriae* lipoprotein of claim 31 and a pharmaceutically acceptable carrier.
- 35. (new) An immunogenic composition comprising an immunogenically effective amount of a nucleic acid sequence selected from the group consisting of a DNA fragment, a recombinant DNA molecule and a live recombinant carrier, or host cell comprising said nucleic acid sequence, wherein said nucleic acid sequence is the nucleic acid sequence of claim 25.
- 36. (new) An immunogenic composition comprising an immunogenically effective amount of a nucleic acid sequence selected from the group consisting of a DNA fragment, a recombinant DNA molecule and a live recombinant carrier, or a host cell comprising said nucleic sequence, wherein said nucleic acid sequence is the nucleic acid sequence of claim 27.

-7-

Attorney Docket: I-2002.011 US

Customer No.: 31846

- 37. (new) A DNA fragment comprising a nucleic acid sequence according to claim 27.
- 38. (new) A recombinant DNA molecule comprising a nucleic acid sequence according to claim 27, under the control of a functionally linked promoter.
- 39. (new) A live recombinant carrier comprising a nucleic acid sequence according to claim 27.
- 40. (new) A host cell comprising a nucleic acid sequence according to claim 27.
- 41. (new) A diagnostic kit for detecting Brachyspira hyodysenteriae or antibodies thereto, comprising a nucleic acid sequence according to claim 27, or a lipoprotein or antigenic fragment thereof encoded by said sequence, or antibodies that are reactive with said lipoprotein.
- 42. (new) A vaccine for combating Brachyspira hyodysenteriae infection, comprising antibodies against a lipoprotein according to claim 31 and a pharmaceutically acceptable carrier.

-8-

Attorney Docket: I-2002.011 US

Customer No.: 31846

- 43. (new) The vaccine according to claim 42, comprising an adjuvant.
- 44. (new) The vaccine according to claim 42, comprising an additional antigen derived from another swine pathogen, an antibody against such an antigen or genetic information encoding said antigen.
- 45. (new) The vaccine according to claim 44, wherein said pathogen is selected from the group constituting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

-9-

Attorney Docket: I-2002.011 US

Customer No.: 31846